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Chaperone-assisted crystallography with DARPins
Abstract
The structure of proteins that are difficult to crystallize can often be solved by forming a noncovalent
complex with a helper protein--a crystallization "chaperone." Although several such applications have
been described to date, their handling usually is still very laborious. A valuable addition to the present
repertoire of binding proteins is the recently developed designed ankyrin repeat protein (DARPin)
technology. DARPins are built based on the natural ankyrin repeat protein fold with randomized surface
residue positions allowing specific binding to virtually any target protein. The broad potential of these
binding proteins for X-ray crystallography is illustrated by five cocrystal structures that have been
determined recently comprising target proteins from distinct families, namely a sugar binding protein,
two kinases, a caspase, and a membrane protein. This article reviews the opportunities of this
technology for structural biology and the structural aspects of the DARPin-protein complexes.
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The structure of proteins which are difficult to crystallize can often be solved by forming 
a non-covalent complex with a helper protein – a crystallization “chaperone”. While a 
number of such applications have been described to date, their handling usually is still 
very laborious. A valuable addition to the present repertoire of binding proteins is the 
recently developed Designed Ankyrin Repeat Protein (DARPin) technology. DARPins 
are built based on the natural ankyrin repeat protein fold with randomized surface 
residue positions allowing specific binding to virtually any target protein. The broad 
potential of these novel binding proteins for X-ray crystallography is illustrated by five 
cocrystal structures that have been determined recently comprising target proteins from 
distinct families, namely a sugar binding protein, two kinases, a caspase and a 
membrane protein. In this article the opportunities of this technology for structural 
biology and the structural aspects of the DARPin-protein complexes are reviewed.  
 
Despite the continuous technical advances in protein crystallography due to the worldwide 
effort in structural genomics programs that promoted the application of automated procedures 
in cloning, expression, purification, crystallization, data collection using synchrotron radiation 
and computational crystallography, the determination of some particular protein structures 
still remains a difficult task. Today the main limitation is the growth of well-diffracting 
crystals - a pure trial-and-error process – as the formation of protein crystals depends on a 
large number of variables that cannot be predicted. Advances particularly in microscaling 
methodology involving pipetting robots and automated imaging of individual experiments 
have allowed high throughput approaches boosting the field. However, even with these 
advances, many proteins simply resist forming suitable crystals on their own, because of 
inherent structural flexibility and instability. Consequently, conformation stabilizing methods 
that help to crystallize proteins seem attractive.  
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Approaches in this direction are removal or mutation of surface residues known to be flexible 
(Lawson et al., 1991), the trimming of the protein’s often flexible N- and C-terminal ends or 
the analysis of stable domains of larger multi-domain proteins (Derewenda, 2004). Another 
successful approach to promote the crystallization of a particular protein has been the addition 
of a conformation-stabilizing ligand. Current crystallization tools include the building of 
complexes with diverse known natural or synthetic ligands, such as substrates, inhibitors, 
nucleic acid, cofactors or protein ligands. The benefits of such non-covalent complexes can be 
manifold. A specific conformation of the target protein may be stabilized in such a complex. 
This increases the chances to obtain crystals of proteins that otherwise adopt several 
conformations and therefore resist forming crystals. In addition, novel surfaces can potentially 
provide better crystal contacts. Especially for membrane proteins, protein ligands also 
increase the hydrophilic surface area of an otherwise often rather small non-transmembrane 
region. This strategy for the crystallization of membrane proteins has repeatedly led to 
successful structure determinations, as seen for many antibody fragment-membrane protein 
complexes (Dutzler et al., 2003; Hunte et al., 2000; Iwata et al., 1995; Zhou et al., 2001). Co-
crystallization of a target protein in complex with a proteinaceous ligand of known structure 
potentially provides another advantage, namely the structure solution by molecular 
replacement allowing to avoid the often time consuming determination of phases via heavy 
atoms as in single/multiple anomalous dispersion (SAD, MAD) or multiple isomorphous 
replacement (MIR) techniques. 
DNA and RNA binding proteins are often cocrystallized with their natural binding partner, 
fragments of DNA or RNA stabilizing the conformation of the protein (Anderson et al., 
1984). In many cases however, the protein of interest lacks a natural binding partner, the 
natural binding partner might not be known or might not be available for other reasons. 
Therefore, proteinaceous ligands, either natural or synthetic, have received a great deal of 
attention in the field of structural biology. Antibody and fragments thereof are the most 
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successful molecules to be used as high affinity and specific binding proteins in biomedical 
research and have pioneered the idea of not only being used as a binding protein but also 
assist in crystallization (Amit et al., 1986). In 1995, Ostermeier et al. selected monoclonal 
antibodies for the first time against a membrane protein, namely cytochrome c oxidase of 
Paracoccus denitrificans, finally allowing the successful structure determination of the 
oxidase in complex with a FV fragment (Iwata et al., 1995; Ostermeier et al., 1995). Besides 
the well-known Fab and Fv fragments also single chain antibody domains such as camelid 
VHH fragments or scFvs led to successful structure determinations (Desmyter et al., 1996; 
Kortt et al., 1994). Recently, several studies using non-antibody scaffolds such as affibodies 
(Hogbom et al., 2003; Wahlberg et al., 2003), monobodies (Koide et al., 2007), and repeat 
proteins (Binz et al., 2004) have shown that these molecules are potential alternatives to 
antibody fragments in structural biology. Originally, all these binding molecules were 
developed as tools for basic research but their potential use in commercial applications (as 
specific reagents in biomedical research and as potential therapeutic molecules) was 
immediately apparent and quickly recognized (Gill and Damle, 2006). Many novel binding 
proteins have improved on the limitations of antibodies, in particular their rather low 
production yield and intrinsic stability. Simultaneously, they retain the beneficial properties of 
antibodies namely specific and tight binding. Structural biologists likewise have a great 
interest to use these molecules as chaperones in crystallization. 
In this review we focus on one novel scaffold, the designed ankyrin repeat proteins 
(DARPins). The potential of DARPins as promising compounds in drug discovery and drug 
development has been recently reviewed (Stumpp and Amstutz, 2007). Here we examine the 
five recently determined X-ray structures of DARPin complexes and address a number of 
questions concerning DARPin-target interactions. The diversity of the successfully chosen 
antigens is paralleled by the diversity of the interaction partners of natural ankyrin repeat 
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proteins which indicates that the technology can be generally applied to a very broad range of 
target molecules.  
 
Drawbacks of antibodies 
The main advantage of antibodies is their ability to recognize a wide range of target molecules 
with high affinity and specificity. Besides proteins, antibodies can bind compounds such as 
peptides, sugars and small molecules. However, natural antibodies are complex multidomain 
molecules not well suited for cocrystallization due to their flexible linker regions between 
domains and their bivalent character. Therefore, only antibody fragments have been applied 
for cocrystallization purposes. Fab or Fv fragments contain the complete antigen recognition 
sites and are therefore sufficient to retain the specific antibody-antigen interaction. 
Nevertheless, these fragments often derive from monoclonal antibodies and their classical 
production by hybridoma technology is time-consuming, expensive and is based on the usage 
of living organisms. The selection using recombinant and synthetic libraries have facilitated 
their generation (Rothe et al., 2008) and led to successful structure determinations (Fellouse et 
al., 2007; Fellouse et al., 2005; Fellouse et al., 2004; Ye et al., 2008) but the complicated 
multidomain molecular architecture with disulfide bonds still complicates their handling, 
limits their use in reducing environments and requires special production precautions in 
bacterial expression systems such as expression in the periplasm to guarantee the correct 
disulfide bond formation. This often affects the production yield since the volume of the 
periplasm is limited. Despite these difficulties there are numerous structures in complex with 
soluble target proteins (Bentley, 1996) as well as more demanding membrane proteins (Hunte 
and Michel, 2002) but the problems associated with all antibody-derived crystallization 
chaperones inspire continuously to search for alternative binding proteins with similar binding 
capabilities but superior properties regarding structure, stability and throughput. 
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What are DARPins?  
DARPins are derived from the ankyrin repeat motif present in numerous naturally occurring 
proteins. In nature, ankyrin repeat containing proteins are involved in a wide variety of 
biological activities and are present in all three superkingdoms (Bork, 1993). Best 
documented is their involvement in specific protein-protein interactions. The diversity of their 
roles in a cellular context is further reflected in their localization, which can be the nucleus, 
cytoplasm and the extracellular space, where these proteins interact with a large diversity of 
partners. The number of repeats presented in a single ankyrin repeat protein and thus involved 
in binding is highly variable so that ankyrin domains can bind to host target molecules that 
vary considerably in size and shape.  
The 33-residue sequence motif of an ankyrin repeat forms a well-defined architecture, 
consisting of a -turn, followed by a pair of antiparallel -helices and a loop that builds the 
connection to the next repeat (Figure 1A). The characteristic secondary structure components 
fold into an L-shaped conformation where the helices form the stem and the loop projects 
outward at an angle of about 90°. Not uncommon are insertions between or within repeats 
mainly in the -turn/loop region (Sedgwick and Smerdon, 1999). These insertions can be 
either a short helical segment or more complex motifs. The fully assembled ankyrin domain is 
elongated and slightly curved manifested particularly in high repeat number ankyrin repeat 
proteins (Figure 1B). In naturally occurring complexes involving ankyrin repeat proteins, the 
concave surface, formed by the -turn and the first -helix, is commonly involved in binding 
the target molecules as shown by the X-ray structures determined to date: p16INK4a-CDK6 
(Russo et al., 1998), p19INK4d-CDK6 (Brotherton et al., 1998; Russo et al., 1998), GABP-
GABP-DNA (Batchelor et al., 1998), IB-NFB (Huxford et al., 1998; Jacobs and 
Harrison, 1998; Malek et al., 2003), p18INK4c-CDK6 (Jeffrey et al., 2000),  CSL-Notch-
Mastermind (Wilson and Kovall, 2006), Nas6-Rpt3 (Nakamura et al., 2007b), Gankyrin-S6 
(Nakamura et al., 2007a). 
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Recently, Plückthun and coworkers have chosen the traits of ankyrin repeat proteins for 
consensus-based protein library design (Binz et al., 2003). Heeding the lessons of nature, they 
created DNA-libraries which encode DARPins consisting of different numbers of repeat 
modules and special capping repeats attached to the N and C termini of the protein (Figure 
1B). Therefore the molecules are termed NxC, where x indicates the number of ankyrin repeat 
modules. The consensus-designed idealized repeat module consists of conserved residues 
essential for the formation and stabilization of the repeat module itself and the interrepeat 
stacking interactions. These positions are invariant and build the framework of the individual 
repeats. In addition, positions not contributing to the structural integrity of the basic fold were 
defined to be adaptive surface residues (Figure 1A). These residues are positioned at the 
typical interface region of the natural ankyrin repeat, namely the tip of the -turn and along 
the exposed surface of the first -helix (Figure 1C). At these positions the introduced 
diversification allows any amino acid except proline and glycine (structurally unfavorable) 
and cysteine (could form unwanted disulfide bonds). This design resulted in a virtually 
unlimited repertoire of molecular surfaces.  
 
The selection process 
The rapid and easy production is a prerequisite for alternative scaffolds suitable for co-
crystallization. Repeat protein libraries (Binz et al., 2004; Binz et al., 2003) can be selected 
using powerful library selection technologies like ribosome display (RD) (Hanes and 
Plückthun, 1997) or phage display (Smith, 1985), finally yielding specific binders to the target 
protein. RD is a complete in vitro technology based on in vitro translation where non-covalent 
ternary complexes consisting of mRNA, ribosome and nascent protein chain are formed. 
These ternary complexes can then be tested for binding to a particular target protein. This 
system thereby guarantees the coupling of the genotype (mRNA) to the phenotype (protein) 
and allows immediate access to the genetic information of the binders. To achieve this, the 
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coding sequence of the protein is genetically fused to a C-terminal spacer, allowing the 
correct folding of the nascent polypeptide chain and the construct lacks a Stop codon thus 
preventing release of the mRNA and the polypeptide from the ribosome. Low temperature 
and high concentrations of magnesium further stabilize the ternary complexes. The 
disassembly of the complexes results from depletion of magnesium and the DNA is recovered 
by reverse transcription. RD is particularly well suited for large libraries since no 
transformation steps limit the applicable library size. Furthermore, as a cellfree system it 
enables the selection of cytotoxic proteins or of proteins with limited in vivo stability. 
All the DARPin binders presented here were isolated from an N3C library and were selected 
by RD. DARPin binders could also be successfully selected from an N2C library but these did 
not yield crystals so far. Ankyrin repeat proteins consisting of four to five repeats in total are 
very abundant in nature (Bork, 1993) and also many of the solved natural ankyrin repeat 
structures in complex with their target display such repeat numbers. The target proteins 
chosen here were all recombinantly expressed, purified and either in vivo biotinylated at a 
specific lysine in the AviTag sequence (MBP, APH, and Caspase-2), in vitro biotinylated at 
diverse lysines on the surface (AcrB) or GST-tagged (Plk-1) for immobilization. Within a few 
RD cycles (usually 3 to 4), it was possible to enrich the resulting residual library with proteins 
that specifically and with high affinity bind to the target.  
A subset of the DARPins obtained by RD was then tested individually for binding using 
approaches suitable for the particular target protein or the intended use of the binder. For 
MBP (Binz et al., 2004) and Plk-1 (Bandeiras et al., 2008) a standard ELISA was applied to 
identify a high-affinity binder. In the case of Caspase-2 an in vitro enzymatic activity test 
combined with a standard ELISA yielded an inhibitor (Schweizer et al., 2007). For APH 
(Amstutz et al., 2005; Kohl et al., 2005) and AcrB (Sennhauser et al., 2007) an in vivo assay 
was applied where the inhibition of the target protein through the DARPins resulted in 
hypersusceptibility of the bacteria. Normally, the DNA of around twenty DARPins obtained 
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from these assays was sequenced per target. The pools often seemed already quite enriched, 
revealing groups with similar sequences although identical sequences were hardly observed. 
Depending on the sequence variability, five to ten complexes were then purified (yields 
between 50 and 200 mg/l), characterized and subjected to crystallization.  
 
Structures of DARPins in complex with different antigens 
Maltose binding protein (MBP): the proof of principle  
As a model protein for the approach of selecting a specific DARPin protein by RD, the 
maltose binding protein from Escherichia coli was chosen and represents the first successful 
example for the selection and crystallization of a particular target protein in complex with a 
DARPin. The structure of the complex was determined at 2.3 Å resolution and the phases for 
this structure could be determined using a known structure of an unselected DARPin 
previously solved (Kohl et al., 2003). This was possible because the size of the DARPin (~18 
kDa) relative to the size of MBP (~43 kDa) was appropriate and there was only one complex 
in the asymmetric unit. Off7 binds the open form of MBP not involving the sugar-binding 
cleft but binding three helices at one side of the elongated MBP (Figure 2A). Four lysines, 
forming a positive surface patch which account for 60 % of the buried surface area of MBP 
upon complexation interact closely with off7 (Figure 3A). 
This first structure showed that the interface between the selected DARPin off7 and MBP 
indeed involves primarily residues from all three randomized repeat modules with the 
randomized repeat module 2 contributing most to the binding (Figure 4A). The two capping 
repeats are not involved in the interaction. The binding interface is comparable to the lower 
limit of natural protein-protein interactions (Jones and Thornton, 1996) (Table 1) and is 
formed by the concave surface of off7 and a convex surface of MBP. It involves mainly 
amino acids at the randomized positions. Off7 contains three framework mutations, of which 
one (H125Y) is involved in MBP binding. The interface on the DARPin is further 
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characterized by seven aromatic residues, four of these tyrosines, which account for 72% of 
the buried surface area of off7 upon complexation. 
 
Aminoglycoside phosphotransferase (3’)-IIIa (APH): the first inhibiting DARPin 
The bacterial kinase APH mediates antibiotic resistance to many pathogenic bacteria and is 
structurally homologous to eukaryotic protein kinases. A highly affine and potent intracellular 
kinase inhibitory DARPin, named 3a, was selected (Amstutz et al., 2005) and the structure of 
APH/3a with bound ADP was determined at a resolution of 2.15 Å with two heterodimeric 
complexes in the asymmetric unit. The DARPin binds to two helical segments in the C-
terminal lobe of APH (Figure 2B, 3B). 
On the DARPin surface, the interaction residues are located mainly on the N-terminal capping 
repeat and on repeat modules 1 and 2 and to a lesser extend on module 3 (Figure 4A). As for 
MBP/off7 there are no interactions involving the C-terminal capping repeat and as a 
consequence there was only weak density visible for this part of the molecule, indicating 
flexibility.  
Whereas the structure of the DARPin is not affected by the binding (Figure 4B), 3a binds to 
the two helices A and B in the -helical C-terminal lobe of APH thereby stabilizing helix D in 
a conformation unable to bind substrate (Figure 5A). In addition, the aminoglycoside 
positioning loop connecting helices A and B is disordered. The structure of the C-terminal 
lobe of the complex differs therefore significantly from the structure of APH alone. This 
affects in particular the C-terminal amino acid Phe264 of helix D which is critically involved 
in substrate binding as revealed by the kanamycin A bound APH structure (Hon et al., 1997). 
In the DARPin complex this interaction is distorted and thus the enzyme is unable to bind the 
antibiotic.  
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Polo-like kinase-1 (Plk-1): an arduously crystallizable target 
The Ser/Thr protein kinase Plk-1 is a key regulator of mitosis and is a well validated drug 
target in cancer therapy. Crystallization attempts for various constructs of the wild-type kinase 
domain of Plk-1 using a multi-parallel cloning and expression approach have failed in the 
past. Therefore binders from a DARPin library selective for Plk-1 have been generated and 
have been used in cocrystallization trials. In this way the first structure of wild-type apo Plk-1 
could be determined in complex with the DARPin 3H10 at 2.3 Å resolution with two 
complexes in the asymmetric unit. The DARPin binds to the C-terminal lobe of the kinase 
directly below the ATP binding site (Figure 2C). The binding epitope recognized by  
DARPin 3H10 is especially rich in Arg, Lys and Glu residues (66% of the buried surface 
area) enabling crystallization by masking a surface patch of Plk-1 that is unfavourable for 
forming crystal contacts similar to the surface residue mutation method (Figure 3C). Such 
residues have high conformational freedom and are considered counterproductive for crystal 
contact formation due to a loss of entropy (Derewenda and Vekilov, 2006). As revealed by 
isothermal calorimetry measurements, the overall interaction is endothermic and apparently 
driven by entropy alone. 
The three repeat modules are solely responsible for the interaction and again there are mainly 
residues at the randomized positions involved (Figure 4A). The N-terminal capping repeat is 
not involved in binding. Interestingly, the C-terminal capping repeat is fully disordered in the 
structure either due to the binding of the kinase or due to clashings with the 
noncrystallographic symmetry related DARPin during crystal formation.  
 
Caspase-2: the first specific Caspase-2 inhibitor 
Caspases are key molecules in the signaling of apoptosis and inflammation. The DARPin F8 
was found to inhibit caspase-2 with a subnanomolar inhibition constant. In addition, testing 
inhibition against other caspases showed that F8 was highly specific exclusively for caspase-
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2. The structure of the caspase-2/F8 complex at 3.24 Å resolution revealed the molecular 
basis for the specificity as well as the allosteric mechanism of inhibition which was also 
verified by kinetic analysis. The asymmetric unit contained three caspase-2 dimers with two 
bound DARPins each (Figure 2D). The main contact surface of caspase-2 is formed by the 
381 loop, involving diverse residues (Figure 3D). Minor interactions involve the N-terminus 
of the other -subunit of the caspase. Regarding F8, all three repeat modules and one 
framework residue in the N-terminal capping repeat are forming the interface on F8 (Figure 
4A).  
The 381 loop forms one side of the active site cleft (Figure 5B). The conformation of this 
loop is slightly shifted when compared to the caspase-2/peptide inhibitor structure (Schweizer 
et al., 2003), resulting in an opening of the active site cleft. Additional rearrangements in the 
surrounding of the active site cleft and the side chain of Tyr79 of F8 occupying partly the 
substrate subpocket S5 of caspase-2 are the main reasons for the inhibitory property of F8. 
The caspase-2/F8 complex shows that the allosteric inhibition of caspase-2 is extremely 
specific which has significant advantages over orthosteric ligands which often lack 
specificity.  
 
AcrB: the first integral membrane protein in complex with a DARPin 
The multidrug exporter AcrB, the inner membrane component of the AcrAB-TolC drug efflux 
system in E. coli is the major system contributing to efflux-caused drug resistance in this 
organism. This protein actively detoxifies the intracellular space by exporting drugs to the cell 
exterior while importing protons. To explain the molecular mechanism of this process, the 
availability of high resolution structural information is a prerequisite. For this, and to show 
the applicability of the DARPin combinatorial libraries and of the ribosome display selection 
method to membrane proteins, AcrB was chosen as model system. Although AcrB can be 
crystallized on its own due to its large periplasmic domain protruding from the lipid bilayer, 
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the crystals of the AcrB/110819 complex diffracted to 2.54 Å resolution, substantially better 
than all the previously published crystals of AcrB alone (Murakami et al., 2002). In the 
structure, the DARPin binds to the periplasmic part of AcrB and due to the distinctly different 
conformations of the subunits only two DARPins bind to the trimeric protein (Figure 2E). 
The epitope on AcrB is mainly formed by a -sheet connecting the pore domain with the 
TolC docking domain, which are subdomains of the periplasmic portion of the protein 
(Figure 3E). An additional interaction is formed involving a helical segment and a -strand of 
the adjacent preceding subunit of AcrB via hydrophobic interactions and two hydrogen bonds. 
All five repeats (including both capping repeats) of the DARPin are involved in the 
interaction (Figure 4A) and comprising around 1100 Å2 buried surface area on both the 
DARPin and AcrB, and 68 residues in total, this complex showed the largest buried surface 
area for a DARPin complex so far (Table 1).  
Interestingly, the structure revealed a new conformation of the molecule where the three 
subunits of AcrB were locked in different conformations revealing distinct channels in each 
subunit. Furthermore the structure indicated how in the protein the coupling between the 
channel access, exit and the putative proton translocation site is achieved. It suggests a 
transport pathway through the identified channels in the individual subunits by a rotary 
mechanism. At the same time this new conformation was also observed without a bound 
DARPin by two individual groups (Murakami et al., 2006; Seeger et al., 2006). In further 
studies, DARPin 110819 also allowed the crystallization of otherwise uncrystallizable 
mutants (K.M. Pos, unpublished results). 
 
General properties of DARPin/target interfaces 
The structural properties forming the surface of the target proteins recognized by DARPins 
varies from complex to complex (Figure 2). A common trait between the different interfaces, 
however, is the overall curvature of the target protein interface area enclosed by DARPins. 
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This curvature is complementary to the curvature of the randomized surface area of the 
DARPin. Furthermore, all three internal randomized repeat modules are involved in the 
interaction in all five complexes (Figure 4A). As set out in the design, the predominant 
interaction is mediated by residues in the randomized positions (Figure 4C). This is then also 
the reason for the high specificity of the selected molecules. Interestingly, the last residue of 
the individual repeat module, namely randomized position 33 is not involved in any interface. 
In contrast, position 3 is heavily buried in most of the repeat modules. In all complexes, also 
framework residues participate in the interaction with the target protein. In the case of the 
MBP and AcrB binders there is a mutated framework position H125Y and D155N, 
respectively, contributing to the interaction. Such framework mutations can be explained as a 
result of the numerous PCR cycles the DARPin-encoding DNA passes during the selection 
process.  
The involvement of the capping repeats in the interface differs greatly between the different 
complexes. Whereas the N-terminal capping repeat is well ordered in all structures and 
involved in binding in the APH, Caspase-2 and AcrB complexes, the C-terminal capping 
repeat is fully disordered in the Plk-1 complex and partially disordered in the APH and 
Caspase-2 complex. It is solely involved in the interface of the AcrB/110819 complex, where 
7 residues of the C-terminal capping repeat are participating in the interface. In having the 
first interacting residue at position 13 and the last at position 157, the full width of the 169 
amino acid residue DARPin is used in this complex. This provides the most extensive 
interaction described to date.  
The structures discussed here show that DARPins are not restricted to recognize any specific 
amino acid sequence or structure on the target. In all cases, the DARPins recognize native, 
nonlinear epitopes (Figure 3). There is no particular chemical character found neither for the 
epitopes (target interface) nor for the paratopes (DARPin interface). There are numerous 
aromatic residues on the paratopes but they seem to be less preferred than in antibody 
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paratopes (Padlan, 1990). An exception is the MBP-off7 complex where the aromatic residues 
account for 72% of the buried surface area of the DARPin. The proportion of aromatic 
residues in the epitopes is low, a fact that has been observed in antibody-antigen interactions 
as well (Davies and Cohen, 1996). Furthermore, charged residues seem to be important for the 
interaction, accounting for nearly half of the contact residues of the epitopes. While all 
DARPins described here are composed of five repeat modules, the total interface sizes on the 
target molecules differ widely. The MBP/off7 complex presents by far the smallest interface 
comprising 40 residues and a combined buried surface area of only 1264 Å2 (Table 1). In 
contrast, the largest interface observed in the AcrB/110819 complex comprises 63 and 68 
residues and buries 1986 and 2328 Å2 of the AcrB surface in the two interfaces formed. All 
other complex interfaces are in-between these values. However, the interface sizes show great 
similarities to naturally occurring ankyrin repeat protein, heterodimeric protein-protein and 
antibody-antigen complexes (Table 1).   
 
Structural rearrangements in the target proteins and the DARPins 
An often raised argument in the field of chaperone-assisted crystallization is that binders 
might induce a conformational change in the target molecules. Since the crystal structures of 
all target proteins chosen are available also without a binding partner, it is possible to 
investigate conformational changes of the targets on DARPin binding. The structures of MBP 
in the open conformation without a ligand (PDB ID code: 1LLS; (Rubin et al., 2002)) and 
complexed MBP are very similar, with an overall C rmsd below 1 Å.  And also in the case 
of AcrB the structures obtained in 2006 (Murakami et al., 2006; Seeger et al., 2006) are 
remarkably similar, considering the size of the protein (rmsd for 3110 C atoms ~ 1 Å). In 
addition, the observed asymmetry in the crystal structure could also be detected in solution 
(Sennhauser et al., 2007). The overall structure of Plk-1 is also very similar to two structures 
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of a mutant solved at the same time, each harbouring a different ligand (Kothe et al., 2007), 
again indicating that there is no binding protein induced conformational change.  
The interaction of the DARPin inhibitors with APH and caspase-2 revealed conformations in 
which the target proteins were inactive. This information is useful for finding novel ways to 
inhibit the function of an enzyme. The structural rearrangements there are quite considerable. 
In APH, helices A, B, and D are significantly shifted with respect to kanamycin A bound 
APH (Hon et al., 1997) and the aminoglycoside positioning loop connecting helices A and B 
is disordered (Figure 5A). In caspase-2, the loops surrounding the active site cleft are altered 
when compared to the caspase-2/peptide inhibitor structure (Schweizer et al., 2003), resulting 
in an opening of the active site cleft (Figure 5B). Nevertheless, we do not believe that these 
structural rearrangements are caused by the DARPin, resulting in an induced fit. Recalling the 
DARPin selection strategy, it is more likely that the DARPins only bind to epitopes as 
presented by the target proteins in a “lock-and-key” like fashion. In this way, the selected 
DARPins can bind to proteins not only in their predominant conformation but also can trap 
the proteins in conformations which are probably present in solution but less populated thus 
inhibiting an enzyme in an allosteric way. 
In all structures, the differences in the DARPin scaffold are minimal upon binding and 
showed no essential rearrangements of the global fold compared to an unselected DARPin 
alone (Kohl et al., 2003) (Figure 4B).  In agreement with the participation of the individual 
repeats in the interaction, the strongest flexibility can be observed in the C-terminal capping 
repeat. In the DARPin binding Plk-1 the C-terminal capping repeat can not even be localized 
in the crystal structure. The -turn regions of the individual repeat modules also show some 
minor adaptations when bound to a target protein.  
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DARPin mediated crystal contacts 
The potential of DARPins to provide crystal contacts is best described for the MBP/off7 and 
the AcrB/110819 complex. As shown in Figure 6A, in the MBP/off7 complex the lattice 
interactions involve only DARPin-DARPin and MBP-MBP contacts which occur within 
layers and the direct binding interface between the two interaction partners is the sole contact 
form between the layers.   
In the crystal formed by the AcrB/110819 complex, crystal contacts are mediated by the 
DARPin in such a way that besides the interaction with the periplasmic domain of its target, 
simultaneously, the convex side of the DARPin forms crystal contacts to the cytoplasmic 
polar surface of a symmetry related molecule of AcrB (Figure 6B). Since the crystal has the 
space group P212121 this contact critically contributes to the stability of the lattice (the 
mentioned contact occurs in all three dimensions) and thus to the higher diffraction limits of 
the complex crystal over the crystal formed by AcrB alone. 
There are some proteins that could be crystallized only when complexed to a cognate Fab 
fragment (Laver et al., 1990). A similar case is Plk-1 that alone in its apo-form - a structure 
most useful for drug design - did not crystallize. In complex with the DARPin 3H10, 
however, Plk-1 did crystallize. Surprisingly, the DARPin makes direct crystal contacts to the 
other DARPin in the asymmetric unit via the third repeat module as the C-terminal capping 
repeat is fully disordered (Figure 6C).  
It is worth to mention that cocrystallization with a DARPin clearly was advantageous in the 
cases of AcrB and Plk-1, while it was the opposite for caspase-2. Here, the diffraction quality 
of the DARPin complex was clearly worse (3.24 Å) than for the caspase-2 in complex with a 
peptide inhibitor (1.65 Å) (Schweizer et al., 2003). DARPins containing different numbers of 
internal repeats might be selected to obtain better diffracting crystals. 
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Conclusions 
We here review the recent results using DARPins as crystallization tools to crystallize 
difficult target proteins and to understand natural and alternative conformations of these 
proteins. DARPins are a novel class of designed binding molecules that represent a very 
promising alternative to antibodies. They retain the affinity and specificity of antibodies but 
are far more stable and their simple architecture allows high-yield bacterial production. Their 
use in biomedical and biotechnological research is considerably more advantageous over 
antibodies. High-affinity DARPins to a given target can rapidly be selected from very large 
libraries within a few weeks. The use of in vitro selection systems such as phage or ribosome 
display represents an advantage over the traditional production of monoclonal antibodies in 
test animals as the binders are selected to a native protein under defined buffer conditions. 
Therefore, the in vitro display techniques guarantee that surface epitopes of the presented 
target protein are selected. The use in structural biology is obvious from the structures 
described here and is not only enabling crystallization of soluble and membrane proteins but 
also revealing conformations of the target proteins that otherwise are not detected, when 
inhibitors are selected. In the cases of DARPin inhibitors of caspase-2 and APH the crystals 
of the complex did not diffract better, the diffraction was rather worse than of crystals of the 
target proteins with small molecule compounds bound to the active site. However in both 
cases a conformation of the target protein was revealed in which the protein is inactive. This 
information is useful for finding novel ways how target protein function might be modulated.   
To expand the applicability of the technology in protein crystallography, heavy atom sites can 
be engineered into the capping repeats. Crystals of target proteins with a heavy atom loaded 
DARPin is a great help in phasing using the single anomalous dispersion method (SAD). This 
has already been successfully applied using a DARPin-MBP complex crystal (A. Plückthun 
and M.G.Grütter, unpublished results). 
18
In conclusion, DARPins have the potential to provide (i) crystals of a target protein that is 
difficult to crystallize, (ii) better diffracting crystals of the complex when the target protein 
alone only poorly diffracts, (iii) initial phases for molecular replacement, in cases where the 
DARPin and the target protein are not too different in size, (iv) phases by SAD for complexes 
formed with heavy atom loaded DARPins, and (v) reveal new insight into the function of a 
target protein by stabilizing a conformation that in solution is less populated.
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Figure and Table Legends 
 
Figure 1. The Structure and potential interaction surface of a DARPin 
 
(A) Ribbon representation of a designed ankyrin repeat module. The side chains of the six 
randomized positions and the randomized framework residue (position 26) are shown as 
yellow sticks and their positions within the 33-amino acid conserved framework are labeled. 
Side chains of the conserved residues are not shown for clarity. 
(B) An N3C DARPin library member. The three repeat modules are colored in purple and the 
capping repeats in blue. The randomized positions, located mainly in the -turns and the first 
-helices of the individual repeat modules, are shown as yellow sticks. 
(C) Randomized potential interaction surface of an N3C DARPin, that normally provides the 
interaction site (in yellow). The orientation is the same as in B.  
All figures were prepared with PyMol (DeLano, 2002). 
 
Figure 2. Open book illustrations of the interaction surfaces of DARPins and their 
respective target molecules 
 
(A)-(D) Center panel: ribbon diagrams of the X-ray structures of the individual complexes. 
Target proteins and DARPins are colored blue and purple, respectively. Interfaces are 
highlighted in yellow. Left panel: The targets have been rotated clockwise. Right panel: The 
DARPins have been rotated counterclockwise. Residues that approach within 4 Å of the 
interaction partner are colored by element (C, N, and O atoms are colored yellow, blue, and 
red, respectively).  
(A) DARPin off7 in complex with MBP (PDB entry code 1svx). 
(B) DARPin 3a in complex with APH (PDB entry code 2bkk). 
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(C) DARPin 3H10 in complex with Plk-1 (PDB entry code 2v5q). 
(D) DARPin F8 in complex with caspase-2 (PDB entry code 2p2c). Caspase-2 is colored dark 
blue for the -subunits and light blue for the -subunits. 
(E) DARPin 110819 in complex with AcrB (PDB entry code 2j8s). The AcrB subunits A, B, 
and C are colored darkblue, lightblue, and gray. Left panel: AcrB has been translated. Right 
panel: the DARPin has been rotated counterclockwise. Residues that approach within 4 Å of 
the DARPin are colored by element.  
 
Figure 3. Comparison of the epitopes on the different target molecules 
 
Stereo view of the targets of the complexes. The molecules are shown in ribbon representation 
in the same orientation as in Figure 2 left panel. Interfacing residues (4 Å distance cutoff) are 
shown as sticks and colored by element. 
(A) MBP  
(B) APH  
(C) Plk-1  
(D) Caspase-2  
(E) Close-up view of AcrB  
 
Figure 4. Structural differences between the binding DARPins 
 
(A) Contribution of each repeat to the buried surface area of the paratope. 
(B) Structures of the DARPins bound to the diverse target molecules. The C atoms of the 
DARPins were least-squares superimposed using the program coot and are shown in worm 
representation. The termini are labeled. The DARPins are colored as follows: red: unselected 
28
DARPin; orange: off7; yellow: 3a; green: 3H10; cyan and light blue: F8 molecules P and Q; 
dark blue and gray: 110819 molecules D and E. 
(C) Amino acid sequence alignment of the DARPins. Positions marked with X and Z in the 
consensus represent the randomized positions where in the case of X any amino acid (except 
Cys, Gly, and Pro) or in the case of Z Asn, His, and Tyr is allowed. Residues marked in 
yellow and green indicate those involved in binding of the target in the crystal structure 
(distance < 4 Å; in green: accounts for more than 5% of the total buried surface area upon 
complex formation).  
 
Figure 5. Conformations of the target molecules 
 
(A) Close-up view of the superposition of the DARPin binding region of APH in complex 
with DARPin inhibitor 3a (blue and purple) and wtAPH (gray). The APH/3a complex 
displays a distorted drug binding site. The -helices A and B in the C-terminal lobe of APH 
interacting with the DARPin are shifted and the aminoglycoside positioning loop between 
these two helices is disordered. This rearrangement leads further to a 5-7 Å shift of helix D 
with respect to wtAPH which includes the C-terminal residue Phe264. Kanamycin A bound to 
wtAPH is shown in yellow and hydrogen bonds to the mainchain carboxyl group of Phe264 
are indicated as dashed lines. 
(B) Close up view of the active-site cleft region of caspase-2. Superimposed caspase-2 bound 
to Ac-LDESD-CHO (colored in gray and yellow) and to the DARPin F8 (colored in blue and 
red) is shown. In the DARPin bound form, the loop 381 and the C-terminal part of the  
subunit (C) which includes the active site cysteine are shifted with respect to the peptide 
bound form.  
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Figure 6. The diverse crystal contacts mediated by DARPins  
 
(A) Crystal packing in the MBP/DARPin complex. The crystals belong to space group P21. 
One complex is shown in ribbon representation and colored dark blue (MBP) and green 
(DARPin). The neighbouring molecules are shown in worm representation in light blue and 
purple. Crystal contacts are mediated mainly between adjacent DARPin and MBP molecules. 
(B) Crystal contacts of AcrB molecules and DARPins. The crystals belong to space group 
P212121. The AcrB subunits A, B, and C are colored dark blue, light blue, and gray. One of 
the two DARPins (in green) bound to the periplasmic part of AcrB mediates essential crystal 
contacts to the cytoplasmic part of a symmetry-related trimer, resulting in a different packing 
to AcrB crystallized without a DARPin.  
(C) Asymmetric unit content of the Plk-1/DARPin crystal. The two complexes are shown in 
ribbon representation and colored in gray and blue (Plk-1) and purple and green (DARPin). 
The N- and C-terminal ends are labeled.  
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Table 1. Structural features of the interfaces of the DARPin-protein complexesa  
 
 
 Complex KD 
(nM)b 
Resolution 
 (Å) 
Nres Buried surface area (Å2) Percentage of 
total surface area 
(%) 
NHB NSB
   Target DARPinTotal Target DARPin Total Target DARPin 
1svx MBP-off7 (B-A)a  4.4 2.3 19 21 40 649 615 1264 4.2 8.1 8 2 
2bkk APH-3a (A-B) 1.7 2.15 21 27 48 925 850 1775 6.7 10.8 15 8 
2v5q Plk1-3H10 (A-D) 75 2.3 21 25 46 857 885 1742 6.0 14.3 14 9 
2p2c C2-F8 (BDA-P) 4.1 3.24 25 26 51 937 885 1822 12.1 10.2 8 9 
 C2-F8 (DBC-Q)   23 25 48 830 809 1639 10.5 9.7 6 9 
2j8s AcrB-110819 (BA-D) 28 2.54 35 33 68 1142 1186 2328 2.5 15.3 12 3 
 AcrB-110819 (AC-E)   32 31 63 969 1017 1986 2.2 13.4 11 2 
 Antibody-antigenc   777 ± 135   8.2 ± 0.7  
 Heterodimeric 
protein-protein 
complexesc 
  983 ± 582   11.1 ± 
2.7  
 
Analyzed with the Protein Interfaces, Surfaces and Assemblies service PISA. The numbers may be at variance 
with those found by the original authors owing to different programs used. Only the interface features of one 
complex are shown when there were several complexes in the asymmetric unit. 
a Characters in parentheses show the chains participating in the interface as designated in the PDB file (target -
DARPin). 
b Affinities were determined by BIAcore technology. For Plk1-3H10 a KD measured by competition ELISA was 
described. 
c According to (Jones and Thornton, 1996). The values for NHB were calculated from the tabulated hydrogen 
bonds/100 Å2 ASA.  
 
Nres – number of residues from the specified molecule that take part in the interface; NHB – number of potential 
hydrogen bonds across the interface; NSB – number of potential salt bridges across the interface.  
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